Recombinant Vaccine Market, By Type (Attenuated Recombinant Vaccines, Vector Recombinant Vaccines, and Subunit Recombinant Vaccines), By Indication (Human Papillomavirus (HPV), Meningococcal, Hepatitis B, Influenza, Rotavirus, Herpes Zoster, and Others), By End User (Pediatric, Adult, and Geriatric), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Vaccination Centers), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

Published In : Jan 2025

Code : CMI455

Pages :156

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Recombinant Vaccine Market Regional Insights

To learn more about this report, Request sample copy

North America Recombinant Vaccine Market Trends

North America’s dominance in the global recombinant vaccine market with a share of 35.3% in 2024 can be attributed to factors like the well-established healthcare infrastructure, favorable government policies supporting vaccine research, and the presence of major players like Pfizer. The region houses top innovators which helped accelerate the development and adoption of novel vaccine technologies.

Asia Pacific Recombinant Vaccine Market Trends

The Asia Pacific region exhibits the fastest growth in the recombinant vaccine market with a share of 27.7% in 2024. This can be largely attributed to rising healthcare spending, growing focus on preventive healthcare among its vastly populated emerging countries, and strategic initiatives by regional governments to broaden immunization programs.

Recombinant Vaccine Market Outlook for Key Countries

U.S. Recombinant Vaccine Market Trends

The U.S. is a leader in the recombinant vaccine market, driven by significant investments in R&D and a robust healthcare infrastructure. In February 2023, Pfizer Inc. announced that the U.S. FDA has accepted a Biologics License Application (BLA) for RSVpreF (PF-06928316), its respiratory syncytial virus (RSV) vaccine candidate. The vaccine aims to prevent medically attended lower respiratory tract illness (MA-LRTI) and severe MA-LRTI in infants up to six months old through active immunization of pregnant individuals.

Germany Recombinant Vaccine Market Trends

Germany's strong pharmaceutical sector supports the recombinant vaccine market, with a focus on advanced manufacturing technologies. The Germany government has increased funding for vaccine research, with a notable investment of USD 750 million announced in March 2021 to enhance vaccine production capabilities.

India Recombinant Vaccine Market Trends

India is emerging as a key player in the recombinant vaccine market, driven by its large population and increasing vaccination rates. The Serum Institute of India, the world's largest vaccine manufacturer, has ramped up the production of recombinant vaccines, contributing to the country's goal of universal immunization.

China Recombinant Vaccine Market Trends

China recombinant vaccine market is expanding rapidly due to government initiatives aimed at improving public health. In April 2021, the Chinese government launched a national vaccination campaign like the National Cervical Cancer Prevention and Control Program, targeting Human Papillomavirus, significantly increasing the demand for recombinant vaccines.